Meningitis and intracranial abscess due to Mycoplasma pneumoniae in a B cell-depleted patient with multiple sclerosis.
Abscess
Anti-CD20 antibody
Complication
Mastoiditis
Multiple sclerosis
Mycoplasma pneumoniae
Ocrelizumab
Rituximab
Septic cerebral venous sinus thrombosis
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
13 Sep 2024
13 Sep 2024
Historique:
received:
04
06
2024
accepted:
28
08
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
12
9
2024
Statut:
aheadofprint
Résumé
Mycoplasma pneumoniae, a frequent respiratory pathogen, can cause neurological disease manifestations. We here present a case of M. pneumoniae as cause of meningitis and occurrence of an intracranial abscess as a complication of mastoiditis with septic cerebral venous sinus thrombosis in a patient with multiple sclerosis on anti-CD20 therapy.
Identifiants
pubmed: 39266884
doi: 10.1007/s10096-024-04935-3
pii: 10.1007/s10096-024-04935-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Davis JS, Ferreira D, Paige E, Gedye C, Boyle M (2020) Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clin Microbiol Rev 33(3). https://doi.org/10.1128/CMR.00035-19
Kappos L, Li D, Calabresi PA et al (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378(9805):1779–1787
doi: 10.1016/S0140-6736(11)61649-8
pubmed: 22047971
Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221–234
doi: 10.1056/NEJMoa1601277
pubmed: 28002679
Steininger PA, Bobinger T, Dietrich W et al (2017) Two cases of severe tick-borne encephalitis in rituximab-treated patients in germany: implications for diagnosis and prevention. Open Forum Infect Dis 4(4):ofx204
doi: 10.1093/ofid/ofx204
pubmed: 29670929
pmcid: 5903409
Grankvist A, Andersson PO, Mattsson M et al (2014) Infections with the tick-borne bacterium “Candidatus Neoehrlichia mikurensis” mimic noninfectious conditions in patients with B cell malignancies or autoimmune diseases. Clin Infect Dis 58(12):1716–1722
doi: 10.1093/cid/ciu189
pubmed: 24647019
Nulens E, Van Praet J, Selleslag D et al (2016) A disseminated Mycoplasma hominis infection in a patient with an underlying defect in humoral immunity. Infection 44(3):379–381
doi: 10.1007/s15010-015-0859-6
pubmed: 26546371
Deetjen P, Maurer C, Rank A, Berlis A, Schubert S, Hoffmann R (2014) Brain abscess caused by Ureaplasma urealyticum in an adult patient. J Clin Microbiol 52(2):695–698
doi: 10.1128/JCM.02990-13
pubmed: 24478517
pmcid: 3911303
Britton PN, Dale RC, Blyth CC et al (2020) Causes and clinical features of childhood encephalitis: a multicenter. Prospective Cohort Study Clin Infect Dis 70(12):2517–2526
pubmed: 31549170
D’Alonzo R, Mencaroni E, Di Genova L, Laino D, Principi N, Esposito S (2018) Pathogenesis and treatment of neurologic diseases associated with mycoplasma pneumoniae infection. Front Microbiol 9:2751
doi: 10.3389/fmicb.2018.02751
pubmed: 30515139
pmcid: 6255859
Pereyre S, Goret J, Bébéar C (2016) Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol 7:974
doi: 10.3389/fmicb.2016.00974
pubmed: 27446015
pmcid: 4916212
Dumke R, Ziegler T (2019) Long-Term Low Rate of Macrolide-Resistant Mycoplasma pneumoniae Strains in Germany. Antimicrob Agents Chemother 63(5). https://doi.org/10.1128/AAC.00455-19
Dumke R, Stolz S, Jacobs E, Juretzek T (2014) Molecular characterization of macrolide resistance of a Mycoplasma pneumoniae strain that developed during therapy of a patient with pneumonia. Int J Infect Dis 29:197–199
doi: 10.1016/j.ijid.2014.07.014
pubmed: 25449256
Nau R, Sörgel F, Eiffert H (2010) Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 23(4):858–883
doi: 10.1128/CMR.00007-10
pubmed: 20930076
pmcid: 2952976
Socan M, Ravnik I, Bencina D, Dovc P, Zakotnik B, Jazbec J (2001) Neurological symptoms in patients whose cerebrospinal fluid is culture- and/or polymerase chain reaction-positive for Mycoplasma pneumoniae. Clin Infect Dis 32(2):E31–E35
doi: 10.1086/318446
pubmed: 11170938
Sarathchandran P, Al Madani A, Alboudi AM, Inshasi J (2018) Mycoplasma pneumoniae infection presenting as stroke and meningoencephalitis with aortic and subclavian aneurysms without pulmonary involvement. BMJ Case Rep 2018. https://doi.org/10.1136/bcr-2017-221831
Dong Y, He Y, Zhou X et al (2022) Diagnosis of mycoplasma hominis meningitis with metagenomic next-generation sequencing: a case report. Infect Drug Resist 15:4479–4486
doi: 10.2147/IDR.S371771
pubmed: 35983300
pmcid: 9380824